Evidence map›Paper›PMID 33980925›Full record

ArticleScientific reports2021

Role of miR-506 in ulcerative colitis associated with primary sclerosing cholangitis.

Agnieszka Kempinska-Podhorodecka, Monika Adamowicz, Ewa Ostrycharz, Mateusz Chmielarz, Maciej Wójcicki, Piotr Milkiewicz, Malgorzata Milkiewicz

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Primary Sclerosing Cholangitis and Inflammatory Bowel Disease: A Review.Journal of clinical and translational hepatology · 2022
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Agnieszka Kempinska-PodhorodeckaDepartment of Medical Biology, Pomeranian Medical University, 70-111, Szczecin, Poland. agnieszkakempinska@interia.eu.
Monika AdamowiczDepartment of Medical Biology, Pomeranian Medical University, 70-111, Szczecin, Poland.
Ewa OstrycharzDepartment of Medical Biology, Pomeranian Medical University, 70-111, Szczecin, Poland.
Mateusz ChmielarzDepartment of Medical Biology, Pomeranian Medical University, 70-111, Szczecin, Poland.
Maciej WójcickiLiver and Internal Medicine Unit, Medical University of Warsaw, 02-097, Warsaw, Poland.
Piotr MilkiewiczLiver and Internal Medicine Unit, Medical University of Warsaw, 02-097, Warsaw, Poland.
Malgorzata MilkiewiczDepartment of Medical Biology, Pomeranian Medical University, 70-111, Szczecin, Poland.
Pomeranian Medical University · PLMedical University of Warsaw · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary sclerosing cholangitis (PSC) is commonly accompanied by ulcerative colitis (UC). MicroRNA-506 modulates expression of genes which are essential for sphingosine-mediated signaling pathway and intestinal mucosa protection. We investigated whether miR-506 and its target genes are involved in phenotypic presentations of colonic inflammation and/or neoplasia. We analyzed serum and colon tissue samples collected from patients with PSC, PSC with concurrent UC (PSC + UC), UC alone, and healthy controls (n = 10 each). MiR-506 was substantially upregulated in ascending colons of PSC and PSC + UC patients, in contrast to sigmoid colons of PSC and UC patients. Upregulation of miR-506 was associated with inhibition of SPHK1, AE2, InsP3R3, and p53. Colonic suppression of miR-506 presented in UC was accompanied by substantially increased DNMT1, SPHK1, and S1P lyase expressions. A functional in vitro analysis in Caco-2 cells showed that the induction of miR-506 activity by miR-506 mimic or GDCDA bile acid suppressed, whereas inhibition of miR-506 by miR-506 inhibitor or lipopolysaccharide (LPS) upregulated the expression of the examined target genes. A different phenotypic presentation of colitis may be related to miR-506 expression. In ascending colons with PSC + UC, upregulation of miR-506 may result in failure of bicarbonate secretion and inhibition of p53, which predisposes to pro-tumorigenic transformation. In contrast, downregulation of miR-506 enhances S1P production, leading to pro-inflammatory signaling.

Indexed as

Disease SusceptibilityAdultBiomarkersCaco-2 CellsCholangitis, SclerosingColitis, UlcerativeGene Expression ProfilingGene Expression RegulationGenetic Predisposition to DiseaseHumansMicroRNAsMiddle AgedModels, BiologicalYoung AdultBiomarkersMicroRNAsMIRN506 microRNA, human

Identifiers

PMID33980925
PMCPMC8114918
OpenAlexW3160050489

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.